International Stem Cell (International Stem Cell) Quality Rank

View and export this data going back to 2006. Start your Free Trial

What is International Stem Cell Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

International Stem Cell Quality Rank Related Terms

Thank you for viewing the detailed overview of International Stem Cell's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

International Stem Cell (International Stem Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » International Stem Cell Corp (OTCPK:ISCO) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

9745 Businesspark Avenue, San Diego, CA, USA, 92131

Website

https://www.internationalstemcell.com

International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. It operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.

Executives

Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Andrei Semechkin	10 percent owner	1 OVERLOOK DR. UNIT 11, AMHERST NH 03031
Sofya Bakalova	officer: Dir. of Legal Affairs & Oper.	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Wright Don	director	2829 RUCKER AVE, 3RD FLOOR, EVERETT WA 98201
Jennifer Stephens	officer: Acting Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Mahnaz Ebrahimi	officer: Chief Financial Officer	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Rouslan Semechkin	director, 10 percent owner	2595 JASON CT, OCEANSIDE CA 92056
Tibor Jay Novak	officer: Interim CFO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
John Simon Craw	officer: Executive Vice President	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
James H Berglund	director	C/O INTERNATIONAL STEM CELL CORPORATION, 5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Ar Partners Llc	10 percent owner	5950 PRIESTLY DR., CARLSBAD CA 92008
Kurt Andrew May	officer: President and COO	5950 PRIESTLY DRIVE, CARLSBAD CA 92008
Linh T Nguyen	officer: Chief Financial Officer	5950 PRIESTLY DR., CARLSBAD CA 92008
Jeffrey Janus	director, officer: President	2595 JASON COURT, OCEANSIDE CA 92056
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027